Argos Therapeutics Licenses Arcelis(R) Technology Platform to Lummy HK for Development of Personalized Immunotherapies to Treat Cancer in China

By: via Benzinga
Argos Therapeutics, Inc. (Nasdaq: ARGS) ("Argos"), a biopharmaceutical company focused on the development and commercialization of fully ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.